• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
KMPH

KMPH

KemPharm, Inc.

NASDAQHealthcareBiotechnologyUS

USD5.81

-0.02 (-0.34%)

Company Profile

CEO

Richard W. Pascoe

IPO Date

2015-04-16

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$5.83

Prev. Close

$5.83

Day Low

$5.79

Day High

$5.97

52W Low

$4.00

52W High

$6.92

Market Cap

$0.20B

Volume

0.06M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

16.0%

Avg Negative

12.1%

Avg Neutral

71.9%

News Feed

KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.

GlobeNewsWire·7/21/2021·↑ positive

Why KemPharm Stock Sank Today

The Motley Fool·6/18/2021·↓ negative

KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement

GlobeNewsWire
·6/18/2021
·↑ positive

KemPharm Issues Letter to Shareholders

GlobeNewsWire·6/16/2021·↑ positive

Why This News Could Help KemPharm Stock Break Out: A Technical Analysis

Benzinga·6/10/2021·↑ positive

KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021

GlobeNewsWire·6/9/2021·↑ positive

KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences

GlobeNewsWire·6/3/2021·↑ positive

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/13/2021·↓ negative

KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA

GlobeNewsWire·5/7/2021·↑ positive

KemPharm to Report First Quarter 2021 Results

GlobeNewsWire·5/6/2021·↓ negative